Recent Updates
Recently added Catalysts

Med-Jet, Traditional Syringe

Phase 1

Psoriasis | Unknown | Dermatology |Community Health Systems, Inc.|Last Updated: Sep 18, 2023

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

ACTIVE_CONTROLLEDBiomarker
Total Trials1
Total Enrollment13

FDA Designations

No designations recorded

Clinical trial landscape

Med-Jet, Traditional Syringe · 1 trial · 1 indication

Early Phase 1 1
NCT04410237Triamcinolone Acetonide Injections in Mild-to-moderate Chronic Plaque Psoriasis With a Novel Needle-free Drug-delivery SystemPsoriasis
COMPLETED13 Analytics
EARLY_PHASE1COMPLETED
Triamcinolone Acetonide Injections in Mild-to-moderate Chronic Plaque Psoriasis With a Novel Needle-free Drug-delivery System
PsoriasisUnlock trial analytics

Study Endpoints

Primary Endpoints

Number of participants with treatment-related adverse events as assessed by CTCASE v5.0
26 Weeks

Validate the safety of the Med-jet needle-free drug-delivery system in combination with triamcinolone acetonide in patients with mild-to-moderate psoriasis.

Secondary Endpoints

Efficacy as measured by the target physician global assessment
26 Weeks
Tolerability as measured by the visual analog pain scores
26 Weeks
Quality of Life metric as assessed by the dermatology life quality assessment
26 Weeks
Unlock Study Endpoints

Study Design & Arms

AllocationNON_RANDOMIZED
MaskingNONE
ModelPARALLEL
PurposeOTHER

Treatment Arms

ArmTypeDescription
Med-JetEXPERIMENTALThe Med-Jet injector is a novel needle-free drug-delivery system, which we believe may be a solution to the impracticalities of ILTA for mild-to-moderate psoriasis. It uses regulated compressed air as a power source to accelerate an injectable fluid through a 0.005" orifice (6x smaller than a 30G needle) to penetrate the skin and deliver medication to a specific anatomical region.12 The drug-delivery device is highly configurable allowing adjustable depth and volume parameters.12 In addition, the high-performance design allows for triggering multiple injection sites rapidly which is practical when needing to treat large surface areas
Traditional SyringeACTIVE_COMPARATORTAC will be injected on a half-plaque while the control half of the plaque will be untreated. A standard sterile disposable 1 ml syringe and 30-gauge needle will be used to inject TAC.

Interventions

NameTypeDescription
Med-JetDEVICEOne half of each psoriasis plaque will be treated with a Med-Jet device and Triamcinolone acetonide (TAC) while the control half will be untreated. One side of the body will be treated using a conventional syringe and the opposite side of the body will be treated using the Med-Jet needle-free injection device to verify efficacy, safety, and pain score
Traditional SyringeOTHEROne half of each psoriasis plaque will be treated with a traditional syringe and Triamcinolone acetonide (TAC) while the control half will be untreated. One side of the body will be treated using conventional syringe and the opposite side of the body will be treated using the Med-Jet needle-free injection device to verify efficacy, safety, and pain score
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to N/A
SexALL
Healthy VolunteersNo
Study Sites1

Inclusion Criteria: * Diagnosed with plaque-type psoriasis defined by either: * A board-certified dermatologist, OR * Dermatology Nurse Practitioner, OR * Skin punch biopsy * Involvement of body surface area (BSA) \< 10% at screening and baseline visit. * The presence of plaque-type psoriasi...

Countries:United States
Unlock Eligibility Criteria